These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 10570433)

  • 1. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
    Engblom P; Rantanen V; Kulmala J; Grènman S
    Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines.
    Engblom P; Rantanen V; Kulmala J; Helenius H; Grènman S
    Br J Cancer; 1999 Jan; 79(2):286-92. PubMed ID: 9888470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Smith JA; Ngo H; Martin MC; Wolf JK
    Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane sensitivity of ovarian carcinoma in vitro.
    Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
    Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.
    Raitanen M; Rantanen V; Kulmala J; Helenius H; Grénman R; Grénman S
    Int J Cancer; 2002 Jul; 100(2):238-43. PubMed ID: 12115575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
    Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
    Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer.
    Aoki Y; Sato T; Tsuneki I; Watanabe M; Kase H; Fujita K; Kurata H; Tanaka K
    Int J Gynecol Cancer; 2002; 12(6):704-9. PubMed ID: 12445246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
    Vasey PA
    J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
    Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
    Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
    Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Docetaxel and ovarian cancer].
    Ray-Coquard I
    Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel: an alternative taxane in ovarian cancer.
    Katsumata N
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The integration of docetaxel into first-line chemotherapy for ovarian cancer.
    Kaye SB;
    Int J Gynecol Cancer; 2001; 11 Suppl 1():31-3. PubMed ID: 11489000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.